Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Comprehensive Report on New Developments and Drug Piplelines for Musculo-Skeletal-Disorders Osteoarthritis

July 15, 2008

Research and Markets (http://www.researchandmarkets.com/research/4a63ca/musculoskeletald) has announced the addition of the “Musculo-Skeletal-Disorders Osteoarthritis” report to their offering.

“Musculo-Skeletal-Disorders Osteoarthritis” contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

– Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

– Keep track of your competitors and partners by better understanding their product pipeline.

– Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

– Maintain a critical competitive advantage.

Key Topics Covered:

RECENT HIGHLIGHTS AND CHANGES

–Recent Highlights and Changes

UPCOMING PATENT EXPIRES BY THERAPY AREA

Osteoarthritis Pipeline Overview

–% of Projects (By Phase of Development)

–No. of Projects by Phase of Development

–Marketed Products Vs. Pipeline Products

Company Overview – Pipeline Projects

–Company Overview – Pipeline Projects

–Top Companies in late stage Osteoarthritis Projects

–ALFA WASSERMANN S.p.A.

–Abiogen Pharma S.p.A.

–Amgen Inc

–Alpharma Inc

–Eli Lilly & Co

–Dainippon Sumitomo Pharma Co., Ltd.

–Genzyme Corporation

–Emisphere Technologies Inc

–IDEA AG

–Glenmark Pharmaceuticals Limited

–NicOx S.A.

–Jerini AG

–Paladin Labs Inc.

–Novartis AG

–Seikagaku Corporation

–Pfizer Inc

–Winston Laboratories, Inc.

–Taisho Pharmaceutical Co., Ltd.

–ZARS Pharma

–Wyeth

–Top Companies in early stage Osteoarthritis Projects

–AnGes MG, Inc.

–Amgen Inc

–AP Pharma Inc

–Antares Pharma Inc

–C&O Pharmaceutical Technology

–ings) Limited

–AstraZeneca Plc

–Echo Therapeutics, Inc

–Dr Reddys Laboratories Ltd

–GlaxoSmithKline plc

–Geron Corporation

–LeukoMed, Inc.

–KAKEN PHARMACEUTICAL CO., LTD.

–Roche Holdings Ltd

–Pharmos Corporation

–Santen Pharmaceutical Co., Ltd.

–Rottapharm SpA

–Shionogi & Co., Ltd.

–Scil Technology GmbH

–XOMA Ltd

–Wyeth

Pipeline Revenue

–Pipeline Revenue

Full Pipeline View

–Pre Clinical Pipeline View

–Phase I Pipeline View

–Phase II Pipeline View

–Phase III Pipeline View

–Pending Approval Pipeline View

–Approved Pipeline View

–On the Market Pipeline View

–Discovery/Development Pipeline View

For more information visit http://www.researchandmarkets.com/research/4a63ca/musculoskeletald.

Source: Life Science Analytics